This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Vivus, Arena Drugs Fail to Burn Americans' Prodigious Fat

Stocks in this article: VVUSARNA

MOUNTAIN VIEW, Calif. ( TheStreet) -- Vivus (VVUS) can't convince enough fat Americans to try its weight-loss pill Qsymia despite spending a ton of cash on marketing and free drug giveaways. At its current burn rate, Vivus will need to raise more money no later than the second half of the year.

Shares of Vivus were down 12% to $10.96 in Tuesday trading.

The dismal $2 million in Qsymia sales reported by Vivus in the fourth quarter is a harbinger of doom for Arena Pharmaceuticals (ARNA), which along with partner Eisai is expected to launch its weight-loss pill Belviq next month. Belviq barely manages to help patients lose any meaningful weight, but will cost significantly more than Qsymia.

Let's first tackle Vivus because the company turned in an ugly quarter Monday night. The $2 million in Qsymia sales was $1 million short of downgraded analyst consensus for the fourth quarter. How downgraded? Last fall, analysts on average were looking for more than $24 million in Qsymia sales during the December quarter.

Vivus spent more than $50 million in SG&A to generate those $2 million in Qsymia sales in the fourth quarter. Add in R&D costs and Vivus' total operating expenses topped $58 million. Cash and marketable securities fell by $61 million sequentially. Vivus ended last year with $213 million in the piggy bank and refused to offer any spending guidance for 2013 except to acknowledge that marketing expenses for Qsymia will remain high.

Even if Qsymia sales pick up, Vivus' current and expected rate of spending means there's less than a year's cash remaining.

For the four-week period ending on Feb. 15, Vivus shipped 17,383 Qsymia prescriptions, a 34% increase over the previous four-week period ended on Jan. 18. That sounds like encouraging script growth, except it's down from 68% growth in the four-week period between November and December last year. Vivus deserves a pass for the December holiday month -- no one wants to lose weight during Christmas -- and sure enough, the number of Qsymia scripts shipped was flat.

Bottom line: The rate of Qsymia script growth is falling despite the company offering freebies and other marketing inducements. Vivus continues to blame Qsymia's poor performance on the hassle of mail-order pharmacy requirements and believes sales will take off once patients can buy the drug at their neighborhood pharmacy. FDA's decision on liberalizing the drug's distribution restriction is expected in April. There's certainly some truth in this spin but Qsymia has a tremendously long way to go before sales reach a meaningful level. The idea that Qsymia might one day achieve blockbuster status or help Vivus generate a profit seems more fantasy than an achievable goal.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,675.11 +213.79 1.30%
S&P 500 1,952.57 +25.46 1.32%
NASDAQ 4,453.6970 +70.85 1.62%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs